ContraVir Pharmaceuticals sets the CRV431 Development’s stage

ContraVir Pharmaceuticals, Inc., a biopharmaceutical organization concentrated on the improvement of restorative medications for the treatment of liver illness emerging from non-alcoholic steatohepatitis (“NASH”) and unending viral contamination, today reported discoveries from a preclinical report where CRV431, a novel cyclophilin…